The success of GLP-1s has prompted biotechs to approach the challenge differently. After years of false starts and disappointing results, longevity drugs could be on the horizon. Do immigrants from some countries commit more sex crimes? And the big business of miniatures. Guests and host:Shailesh Chitnis, global business writerJames Fransham, data correspondentSascha Lowdermilk, culture internỌrẹ Ogunbiyi, co-host of “The Intelligence”Topics covered: Longevity drugs, biotechnology, ageingImmigration, sex crime, BritainMiniatures, 3D printing, hobbiesListen to what matters most, from global politics and business to science and technology—subscribe to The Economist. Hosted on Acast. See acast.com/privacy for more information.
Trending
- Russia says it hit Ukrainian postal hub and ship as Ukraine strikes Ryazan
- It’s Gaza, stupid
- Bomb threat diverts Dublin-Rome flight to France
- Israel extends detention of Palestinian journalist Abed Abou Shhadeh
- US sanctions Indian and Turkish firms accused of helping Iran
- A month after Yemen government offensive began, war of attrition takes hold
- France gears up for strikes and protests as unions promise national mobilisation
- Was an Italian chef really fired over refusal to put pineapple on pizza?
